Home › Compare › TRNLY vs ABBV
TRNLY yields 95.24% · ABBV yields 3.06%● Live data
📍 TRNLY pulled ahead of the other in Year 1
Combined, TRNLY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRNLY + ABBV for your $10,000?
The Trendlines Group Ltd. is an innovation commercialization company and a private equity and venture capital firm specializing in incubation, seed, start-up, early venture and late venture investments. The firm seeks to invest in food, clean technology, agritechnology, lifesciences with a focus on medical devices, biotechnology, and pharmaceuticals, security, medical, and information technology companies. It considers investments in Israel and Singapore. The firm offers business incubation, partner and channel development, market strategies, business plans, research and development and commercialization activities, business development, finance and funding strategies, administrative services and marketing communications services to entrepreneurs. The firm seeks to invest a minimum of $0.06 million in its portfolio companies. The firm prefers to exit its investments through merger and acquisition transactions, listing on public stock exchanges, or other dispositions of holdings. It leverages its own capital with government funding to mitigate risk in creating and developing new businesses. It is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group Ltd. was founded in 1993 and is based in M.P. Misgav, Israel with additional offices in Tel Aviv, Israel; Beijing, China; and Singapore, Singapore.
Full TRNLY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.